Nitric oxide is a key component in inflammation-accelerated tumorigenesis

Cancer Research

Volumn 68, Issue 17, 2008, Pages 7130-7136

  Hussain, S Perwez ^a   He, Peijun ^a   Subleski, Jeffery ^c   Hofseth, Lorne J ^e   Trivers, Glenwood E ^a   Mechanic, Leah ^g   Hofseth, Anne B ^e   Bernard, Mark ^a   Schwank, Jonathan ^a   Nguyen, Giang ^b   Mathe, Ewy ^a   Djurickovic, Draginja ^a   Haines, Diana ^d   Weiss, Jonathan ^c   Back, Timothy ^c   Gruys, Eilene ^c   Laubach, Victor E ^f   Wiltrout, Robert H ^c   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SAIC FREDERICK INC   (United States)

^e UNIVERSITY OF SOUTH CAROLINA   (United States)

^f UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^g WESTAT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; KI 67 ANTIGEN; NITRIC OXIDE; PROTEIN KINASE B; PROTEIN P53; SERINE; TRANSCRIPTION FACTOR FOXP3; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; CRYPTOSPORIDIUM PARVUM; DENDRITIC CELL; INFLAMMATION; LYMPHOMA; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY T LYMPHOCYTE; ANIMAL; C57BL MOUSE; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERFERON TYPE II; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; NITRIC OXIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 52049083887     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0410     Document Type: Article

References (50)

1. Rees DD, Cunha FQ, Assreuy J, Herman AG, Moncada S. Sequential induction of nitric oxide synthase by Corynebacterium parvum in different organs of the mouse. Br J Pharmacol 1995;114:689-93.
2. Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 2006;355:2003-11.
3. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3:276-85.
4. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006;6:521-34.
5. Hussain SP, Trivers GE, Hofseth LJ, et al. Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res 2004;64:6849-53.
6. Lancaster JR, Jr., Xie K. Tumors face NO problems? Cancer Res 2006;66:6459-62.
7. Zamora R, Vodovotz Y, Billiar TR. Inducible nitric oxide synthase and inflammatory diseases. Mol Med 2000;6:347-73.
8. Geller DA, Billiar TR. Molecular biology of nitric oxide synthases. Cancer Metastasis Rev 1998;17:7-23.
9. Forrester K, Ambs S, Lupold SE, et al. Nitric oxide-induced p53accumu lation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci U S A 1996;93:2442-7.
10. Ambs S, Ogunfusika MO, Merriam WG, Bennett WP, Billiar TR, Harris CC. Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci U S A 1998;95:8823-8.
11. Geller DA, Nussler AK, Di Silvio M, et al. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc Natl Acad Sci U S A 1993;90:522-6.
12. Wiltrout RH, Mathieson BJ, Talmadge JE, et al. Augmentation of organ-associated natural killer activity by biological response modifiers. Isolation and characterization of large granular lymphocytes from the liver. J Exp Med 1984;160:1431-49.
13. Kim SF, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005;310:1966-70.
14. Ying L, Marino J, Hussain SP, et al. Chronic inflammation promotes retinoblastoma protein hyperphosphorylation and E2F1 activation. Cancer Res 2005;65:9132-6.
15. Hofseth LJ, Saito S, Hussain SP, et al. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A 2003;100:143-8.
16. Fogler WE, Volker K, Watanabe M, et al. Recruitment of hepatic NK cells by IL-12 is dependent on IFN-γ and VCAM-1 and is rapidly down-regulated by a mechanism involving T cells and expression of Fas. J Immunol 1998;161:6014-21.
17. Xie K, Huang S. Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency. Free Radic Biol Med 2003;34:969-86.
18. Ridnour LA, Thomas DD, Donzelli S, et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal 2006;8:1329-37.
19. Li CQ, Trudel LJ, Wogan GN. Genotoxicity, mitochondrial damage, and apoptosis in human lymphoblastoid cells exposed to peroxynitrite generated from SIN-1. Chem Res Toxicol 2002;15:527-35.
20. Tretyakova NY, Burney S, Pamir B, et al. Peroxynitrite-induced DNA damage in the supF gene: correlation with the mutational spectrum. Mutat Res 2000;447:287-303.
21. Marnett LJ, Wright TL, Crews BC, Tannenbaum SR, Morrow JD. Regulation of prostaglandin biosynthesis by nitric oxide is revealed by targeted deletion of inducible nitric-oxide synthase. J Biol Chem 2000;275:13427-30.
22. Wright KM, Deshmukh M. Restricting apoptosis for postmitotic cell survival and its relevance to cancer. Cell Cycle 2006;5:1616-20.
23. Li CQ, Wogan GN. Nitric oxide as a modulator of apoptosis. Cancer Lett 2005;226:1-15.
24. Chung HT, Pae HO, Choi BM, Billiar TR, Kim YM. Nitric oxide as a bioregulator of apoptosis. Biochem Biophys Res Commun 2001;282:1075-9.
25. Kim PK, Zamora R, Petrosko P, Billiar TR. The regulatory role of nitric oxide in apoptosis. Int Immunopharmacol 2001;1:1421-41.
26. Melino G, Bernassola F, Catani MV, et al. Nitric oxide inhibits apoptosis via AP-1-dependent CD95L transactivation. Cancer Res 2000;60:2377-83.
27. Frigerio S, Silei V, Ciusani E, Massa G, Lauro GM, Salmaggi A. Modulation of fas-ligand (Fas-L) on human microglial cells: an in vitro study. J Neuroimmunol 2000;105:109-14.
28. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
29. Prueitt RL, Boersma BJ, Howe TM, et al. Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer 2007;120:796-805.
30. Irie HY, Pearline RV, Grueneberg D, et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 2005;171:1023-34.
31. Sandau KB, Faus HG, Brune B. Induction of hypoxia-inducible-factor 1 by nitric oxide is mediated via the PI 3K pathway. Biochem Biophys Res Commun 2000;278:263-7.
32. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-7.
33. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11-22.
34. de Vera ME, Shapiro RA, Nussler AK, et al. Transcriptional regulation of human inducible nitric oxide synthase (NOS2) gene by cytokines: initial analysis of the human NOS2 promoter. Proc Natl Acad Sci U S A 1996;93:1054-9.
35. Deakin AM, Payne AN, Whittle BJ, Moncada S. The modulation of IL-6 and TNF-α release by nitric oxide following stimulation of J774 cells with LPS and IFN-γ. Cytokine 1995;7:408-16.
36. Schwentker A, Vodovotz Y, Weller R, Billiar TR. Nitric oxide and wound repair: role of cytokines? Nitric Oxide 2002;7:1-10.
37. Kim YM, Talanian RV, Li J, Billiar TR. Nitric oxide prevents IL-1β and IFN-γ-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1β-converting enzyme). J Immunol 1998;161:4122-8.
38. Schafer ZT, Brugge JS. IL-6 involvement in epithelial cancers. J Clin Invest 2007;117:3660-3.
39. Grivennikov S, Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 2008;13:7-9.
40. Sansone P, Storci G, Tavolari S, et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007;117:3988-4002.
41. Gao SP, Mark KG, Leslie K, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007;117:3846-56.
42. Fontenot JD, Rudensky AY. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005;6:331-7.
43. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804-11.
44. Niedbala W, Cai B, Liew FY. Role of nitric oxide in the regulation of T cell functions. Ann Rheum Dis 2006;65 Suppl 3:iii37-40.
45. Niedbala W, Wei XQ, Campbell C, Thomson D, Komai-Koma M, Liew FY. Nitric oxide preferentially induces type 1 T cell differentiation by selectively upregulating IL-12 receptor h 2 expression via cGMP. Proc Natl Acad Sci U S A 2002;99:16186-91.
46. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006;311:17-58.
47. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005;5:296-306.
48. Paolucci C, Burastero SE, Rovere-Querini P, et al. Synergism of nitric oxide and maturation signals on human dendritic cells occurs through a cyclic GMP-dependent pathway. J Leukoc Biol 2003;73:253-62.
49. Lu L, Bonham CA, Chambers FG, et al. Induction of nitric oxide synthase in mouse dendritic cells by IFN-γ, endotoxin, and interaction with allogeneic T cells: nitric oxide production is associated with dendritic cell apoptosis. J Immunol 1996;157:3577-86.
50. Yamazaki S, Inaba K, Tarbell KV, Steinman RM. Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity. Immunol Rev 2006;212:314-29.